Biocon expands Yesintek biosimilar licensing rights to nine additional international markets

Biocon has secured additional licensing rights for its Yesintek ustekinumab biosimilar across nine international markets, broadening its planned commercial footprint.
The agreement with Janssen Sciences Ireland covers Yesintek, a proposed biosimilar to Stelara, in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan.
The new rights extend Biocon's previously established market-entry arrangements, although financial terms were not disclosed and commercial launches remain dependent on applicable national regulatory approvals.
Field | Content |
Article Type | Deals |
Companies | Biocon; Janssen Sciences Ireland |
Deal Type | International biosimilar licensing and market-entry agreement |
Licensee | Biocon |
Licensing Counterparty | Janssen Sciences Ireland |
Product | Yesintek |
Active Ingredient | Ustekinumab |
Reference Medicine | Stelara |
Product Category | Proposed biosimilar |
Therapeutic Area | Immunology; immune-mediated inflammatory diseases |
Newly Covered Markets | Australia; Brazil; China; Hong Kong; Israel; Mexico; New Zealand; South Korea; Kazakhstan |
Number of Additional Markets | 9 |
Existing Market Context | Previously secured market-entry rights in the United States and other major regions |
Financial Terms | Not disclosed |
Upfront Payment | Not disclosed |
Milestone Payments | Not disclosed |
Royalties | Not disclosed |
Regulatory Status | Country-specific regulatory approvals remain necessary where applicable |
Commercial Launch Timing | Not confirmed in supplied summary |
Announcement Date | 26 October 2026 |
What Happened | Biocon entered an agreement with Janssen Sciences Ireland expanding Yesintek market-entry rights to nine additional international territories. |
Why It Matters | The agreement increases the potential geographic reach of Biocon's ustekinumab biosimilar and could support future biosimilar competition in additional markets. |
Strategic Rationale | Expand Biocon's international biosimilar commercialisation opportunities through additional licensed territories. |
Regulatory Distinction | The announcement concerns licensing and market-entry rights, not nine new marketing authorisations. |
Key Takeaway | Biocon has secured Yesintek rights across nine additional markets, with actual commercialisation subject to national regulatory requirements. |
What to Watch | Country-specific approvals, launch schedules, pricing, reimbursement decisions, supply arrangements and market uptake. |
Primary Source | Biocon |
Primary Source URL | https://www.biocon.com/biocon-secures-market-entry-for-yesintek-a-proposed-biosimilar-to-stelara-in-additional-global-markets/ |
Relevant Date | 26 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comentarios